Patent · US Active

Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors

US7919101B2 · kind B2 · utility

0Cited by

0References

10Claims

0Family size

Assignee

New York Blood Center, Inc. · US

Inventors

Shibo Jiang · Floral Park, US
Chungen Pan · Floral Park, US

Key dates

Filing date	Aug 12, 2009
Grant date	Apr 5, 2011
Priority date	—
Expiry date	Aug 12, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16122
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are pharmaceutical compositions for the prophylactic and therapeutic treatment of HIV comprising combinations of HIV fusion/entry inhibitors that exhibit synergistic effect, including T-20 (enfuvirtide), T-1249, T-1144, C34, and sifuvirtide. Also disclosed are methods of treating HIV infection by administering such compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.